Targeted therapies for advanced non-small cell lung cancer
Metrics: PDF 974 views | HTML 1287 views | ?
Xiaojuan Ai1, Xialing Guo2, Jun Wang1, Andreea L. Stancu3, Patrick M.N. Joslin4, Dianzheng Zhang5 and Shudong Zhu1,2
1National Key Discipline of Genetics, School of Life Sciences, Central South University, Changsha, China
2Argus Pharmaceuticals, Changsha, China
3Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
4Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
5Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA
Shudong Zhu, email: firstname.lastname@example.org
Keywords: NSCLC; molecular target; mTOR; EGFR; PI3K
Received: August 23, 2017 Accepted: February 24, 2018 Published: December 25, 2018
Lung cancer is a serious health problem and the leading cause of cancer death worldwide, due to its high incidence and mortality. 85% of lung cancers are represented by the non-small cell lung cancer (NSCLC). Traditional chemotherapy has been the main treatment option in NSCLC. However, it is often associated with limited efficacy and overall poor patient survival. In recent years, molecular targeting has achieved great progress in therapeutic treatment of cancer and plays a crucial role in the current clinical treatment of NSCLC, due to enhanced efficacy on cancer tissues and reduced toxicity for normal tissues. In this review, we summarize the current targeting treatment of NSCLC, including inhibition of the epidermal growth factor receptor (EGFR), phosphatidylinositol 3-kinase (PI3Ks), mechanistic target of rapamycin (mTOR), epidermal growth factor receptor 2 (ErbB2), vascular epidermal growth factor receptor (VEGFR), kirsten human rat sarcoma protein (KRAS), mesenchymal-epithelial transition factor or hepatocyte growth factor receptor (c-MET), anaplastic lymphoma kinase (ALK), v-Raf murine sarcoma viral oncogene homolog B (BRAF). This article may serve as a guide to clinicians and researchers alike by assisting in making therapeutic decisions. Challenges of acquired drug resistance targeted therapy and imminent newer treatment modalities against NSCLC are also discussed.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.